Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:CGON NYSE:JNJ NASDAQ:UPB NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$20.82+7.8%$18.94$15.47▼$36.37$783.39M1.11348,848 shs433,678 shsCGONCG Oncology$40.71+7.1%$31.36$14.80▼$42.27$2.90B1.311.11 million shs1.90 million shsJNJJohnson & Johnson$189.75+0.5%$177.49$140.68▼$190.22$454.91B0.48.84 million shs5.75 million shsUPBUpstream Bio$18.92+1.3%$17.50$5.14▼$29.46$1.01BN/A453,305 shs328,407 shsUPBUpstream Bio$18.92+1.3%$17.50$5.14▼$29.46$1.01BN/A453,305 shs328,407 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+7.82%+12.78%+3.02%-5.49%-23.99%CGONCG Oncology+7.13%+3.17%+20.84%+50.17%+16.92%JNJJohnson & Johnson+0.42%+2.02%+6.42%+20.31%+18.86%UPBUpstream Bio+1.34%+1.56%+1.01%+59.80%+1,891,999,900.00%UPBUpstream Bio+1.34%+1.56%+1.01%+59.80%+1,891,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$20.82+7.8%$18.94$15.47▼$36.37$783.39M1.11348,848 shs433,678 shsCGONCG Oncology$40.71+7.1%$31.36$14.80▼$42.27$2.90B1.311.11 million shs1.90 million shsJNJJohnson & Johnson$189.75+0.5%$177.49$140.68▼$190.22$454.91B0.48.84 million shs5.75 million shsUPBUpstream Bio$18.92+1.3%$17.50$5.14▼$29.46$1.01BN/A453,305 shs328,407 shsUPBUpstream Bio$18.92+1.3%$17.50$5.14▼$29.46$1.01BN/A453,305 shs328,407 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+7.82%+12.78%+3.02%-5.49%-23.99%CGONCG Oncology+7.13%+3.17%+20.84%+50.17%+16.92%JNJJohnson & Johnson+0.42%+2.02%+6.42%+20.31%+18.86%UPBUpstream Bio+1.34%+1.56%+1.01%+59.80%+1,891,999,900.00%UPBUpstream Bio+1.34%+1.56%+1.01%+59.80%+1,891,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 2.78Moderate Buy$39.1488.01% UpsideCGONCG Oncology 2.79Moderate Buy$58.8244.48% UpsideJNJJohnson & Johnson 2.73Moderate Buy$189.880.07% UpsideUPBUpstream Bio 2.60Moderate Buy$56.50198.63% UpsideUPBUpstream Bio 2.60Moderate Buy$56.50198.63% UpsideCurrent Analyst Ratings BreakdownLatest UPB, CGON, AVBP, JNJ, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AVBPArriVent BioPharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CGONCG OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025JNJJohnson & JohnsonWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)10/8/2025UPBUpstream BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025UPBUpstream BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025CGONCG OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.0010/7/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$200.00 ➝ $213.0010/6/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$172.00 ➝ $193.0010/3/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$198.0010/3/2025JNJJohnson & JohnsonWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight ➝ Overweight$170.00 ➝ $212.0010/3/2025JNJJohnson & JohnsonWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$170.00 ➝ $212.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.65 per shareN/ACGONCG Oncology$1.14M2,722.93N/AN/A$9.63 per share4.23JNJJohnson & Johnson$88.82B5.14$13.18 per share14.40$29.69 per share6.39UPBUpstream Bio$2.37M430.37N/AN/A$8.77 per share2.16UPBUpstream Bio$2.37M430.37N/AN/A$8.77 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$80.49M-$4.02N/AN/AN/AN/A-55.40%-51.97%11/13/2025 (Estimated)CGONCG Oncology-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3520.2917.142.4125.00%32.49%13.00%10/14/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)Latest UPB, CGON, AVBP, JNJ, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/14/2025Q3 2025JNJJohnson & Johnson$2.78N/AN/AN/A$23.73 billionN/A8/11/2025Q2 2025AVBPArriVent BioPharma-$0.70-$0.90-$0.20-$0.90N/AN/A8/8/2025Q2 2025CGONCG Oncology-$0.49-$0.54-$0.05-$0.54$0.11 millionN/A8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 million8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 million7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.74%N/A55.61%64 YearsUPBUpstream BioN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ALatest UPB, CGON, AVBP, JNJ, and UPB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A12.7412.74CGONCG OncologyN/A22.1522.15JNJJohnson & Johnson0.501.010.76UPBUpstream BioN/A38.2738.27UPBUpstream BioN/A38.2738.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%CGONCG Oncology26.56%JNJJohnson & Johnson69.55%UPBUpstream BioN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma18.58%CGONCG Oncology7.40%JNJJohnson & Johnson0.16%UPBUpstream Bio13.56%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4040.57 million33.03 millionN/ACGONCG Oncology6176.25 million70.61 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableUPBUpstream Bio3853.91 million46.60 millionN/AUPBUpstream Bio3853.91 million46.60 millionN/AUPB, CGON, AVBP, JNJ, and UPB HeadlinesRecent News About These CompaniesUpstream Bio management to meet with Piper SandlerOctober 7 at 10:08 PM | msn.comWilliam Blair Sticks to Their Buy Rating for Upstream Bio, Inc. (UPB)October 7 at 2:04 AM | theglobeandmail.comUpstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past WeekOctober 4, 2025 | finance.yahoo.comUpstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Buy" from BrokeragesOctober 3, 2025 | marketbeat.comUpstream Bio’s verekitug shows prevention of TSLP binding in respiratory diseaseSeptember 30, 2025 | msn.comUpstream Bio (NASDAQ:UPB) Trading 4.2% Higher - Still a Buy?September 30, 2025 | marketbeat.comUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European ...September 30, 2025 | finance.yahoo.comUpstream Bio, Inc. Presents Data on Verekitug's Mechanism of Action at ERS Congress, Highlighting Its Potential in Treating TSLP-Driven Severe Respiratory DiseasesSeptember 30, 2025 | quiverquant.comQUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society CongressSeptember 30, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Shares Down 5.3% - Here's What HappenedSeptember 18, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading 5.9% Higher - Still a Buy?September 17, 2025 | marketbeat.comUpstream Bio, Inc. (UPB): A Bull Case TheorySeptember 16, 2025 | msn.comTD Cowen Remains a Buy on Upstream Bio, Inc. (UPB)September 10, 2025 | theglobeandmail.comUpstream Bio Announces Positive Phase 2 Trial ResultsSeptember 9, 2025 | theglobeandmail.comUpstream Bio, Inc. CEO Rand Sutherland to Speak at Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | quiverquant.comQUpstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | globenewswire.comUpstream Bio, Inc. - Special CallSeptember 7, 2025 | seekingalpha.comUpstream Bio, Inc. (UPB) Special Call - SlideshowSeptember 5, 2025 | seekingalpha.comUpstream Bio Shares Rise on Positive Data for Sinus-Disease TreatmentSeptember 3, 2025 | marketwatch.comPositive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for VerekitugSeptember 2, 2025 | tipranks.comChasing pharma heavyweights, Upstream posts phase 2 sinusitis win but stock flows downhillSeptember 2, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 20253 Dividend Stocks to Hold Through Market Volatility This FallBy Chris Markoch | September 16, 2025Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma GiantsBy Gabriel Osorio-Mazilli | October 6, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 2025UPB, CGON, AVBP, JNJ, and UPB Company DescriptionsArriVent BioPharma NASDAQ:AVBP$20.82 +1.51 (+7.82%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$20.82 0.00 (0.00%) As of 10/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.CG Oncology NASDAQ:CGON$40.71 +2.71 (+7.13%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$41.54 +0.83 (+2.04%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Johnson & Johnson NYSE:JNJ$189.75 +0.86 (+0.46%) Closing price 10/8/2025 03:59 PM EasternExtended Trading$189.40 -0.34 (-0.18%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Upstream Bio NASDAQ:UPB$18.92 +0.25 (+1.34%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$19.01 +0.09 (+0.48%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Upstream Bio NASDAQ:UPB$18.92 +0.25 (+1.34%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$19.01 +0.09 (+0.48%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
